Integer Holdings Corporation
Case Overview
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 02/09/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Integer Holdings Corporation |
| Court: | Court: Southern District of New York |
| Case Number: | Case Number: 1:25cv10251 |
| Class Period: | Class Period: 07/25/2024 - 10/22/2025 |
| Ticker: | Ticker: ITGR |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The Class Action alleges that, during the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose that: (1) Integer materially overstated its competitive position within the growing EP manufacturing market; (2) despite Integer's claims of strong visibility into customer demand, the Company was experiencing a sustained deterioration in sales relating to two of its EP devices; (3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for the Company's C&V segment; (4) as a result of the above, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The truth emerged before markets opened on October 23, 2025, when Integer disclosed that it had lowered its full-year 2025 sales guidance to a range between $1.840 billion and $1.854 billion, which fell short of analysts' estimates. Integer further disclosed that it expected net sales growth of -2% to 2% and organic sales growth of 0% and 4% for the full year of 2026. During the corresponding earnings call, COO Khales revealed that Integer "expect[s] sales of [three] new products to decline in 2026," with two of three being "electrophysiology [EP] products." COO Khales further revealed that "the market adoption of these products has been slower than forecasted." During the same earnings call, CFO Smith informed investors that, for the fourth quarter of 2025, "we expect C&V sales growth to decelerate from recent trends, reflecting a decline in the [two] new products in electrophysiology mentioned earlier. This is consistent with our prior outlook. However, we now expect this impact to continue into 2026, primarily the first half." On this news, Integer common stock fell $35.22 per share, or more than 32%, from a closing price of $109.11 per share on October 22, 2025, to a closing price of $73.89 per share on October 23, 2025.